13F Holdings
中文EN

SMMT Summit Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1599298 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY15.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-220.0%
ROA-174.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-64.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$0$0$705,000$1.81M
R&D expense$537.67M$150.78M$59.47M$52.00M$85.35M
SG&A expense$556.75M$60.21M$29.26M$26.74M$23.61M
Operating income—-$226.00M-$609.65M-$72.09M-$86.19M
Interest expense$0$8.69M$16.46M$4.40M$242,000
Pretax income-$1.08B-$221.31M-$614.93M-$78.78M-$88.60M
Income tax$0$0$0—$0
Net income-$1.08B-$221.31M-$614.93M-$78.78M-$88.60M
EBITDA—-$225.91M-$609.45M-$71.74M-$85.86M
EPS (basic)-1.44-0.31-0.99-0.41-0.67
EPS (diluted)-1.44-0.31-0.99-0.41-0.67
Weighted avg. shares (diluted)747.70M718.54M619.65M193.34M131.71M
Balance sheet
Cash & equivalents$225.27M$105.19M$71.42M$648.61M$71.79M
Short-term investments$488.18M$307.49M$114.82M$0—
Receivables——$0$349,000$1.46M
Current assets$720.30M$423.75M$189.71M$656.71M$97.31M
PP&E, net$1.06M$254,000$204,000$906,000$694,000
Goodwill$2.00M$1.86M$1.89M$1.80M$2.01M
Intangibles—$0$0$0$10.40M
Total assets$751.18M$435.56M$202.95M$664.17M$113.37M
Current liabilities$72.99M$41.73M$20.41M$38.78M$25.62M
Total liabilities$92.32M$46.81M$125.26M$537.51M$30.09M
Shareholders' equity$658.86M$388.75M$77.69M$126.65M$83.28M
Shares outstanding775.37M737.63M701.66M211.09M98.04M
Cash flow statement
Operating cash flow-$322.93M-$142.11M-$76.76M-$41.58M-$72.59M
Capital expenditure$657,000$139,000$128,000$624,000$306,000
Free cash flow-$323.59M-$142.25M-$76.89M-$42.21M-$72.89M
Investing cash flow-$174.31M-$205.34M-$587.77M-$624,000-$306,000
Financing cash flow$617.53M$381.23M$86.51M$620.24M$77.92M
Depreciation & amortization$146,000$89,000$198,000$349,000$330,000
Stock-based compensation$732.42M$50.98M$14.11M$11.95M$12.80M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.